Ligand Pharmaceuticals (LGND) Stock Forecast & Price Prediction

Estimation of the future price movement of Ligand Pharmaceuticals stock, based on various factors such as historical price trends, market trends, company performance, and economic conditions.

Price target


Current $59.77

Concensus $90.00


Low $90.00

Median $90.00

High $90.00

Based on analysts projections #LGND is expected to experience a positive growth trajectory over the next year.

The current average LGND price target, as estimated by these analysts, is $90.00.

The predictions for the future LGND stock price range from a low of $90.00 to a high of $90.00, highlighting the variability of market expectations for LGND.

It is important to note that market fluctuations and unforeseen events can have an impact on these projections, so investors should always exercise caution and conduct thorough research before making any investment decisions.

LGND stock forecasts by analyst

Analyst / firm Date Rating Price target Price when posted
Roth Capital December 23, 2022 Buy 90.00 67.32

Ligand Pharmaceuticals (LGND) Fundamentals Checker

Financial metrics are used to evaluate financial stability which helps analysts determine if Ligand Pharmaceuticals is undervalued compared to its fair value. A company's financial health can strongly influence the stock forecast.

Buy

Financial Scores

Updated on: 07/12/2023

Altman Z-Score: 7.4

Piotroski Score: 7.0

ESG Score

Updated on: 07/12/2023

Environmental: 74.6

Social: 70.1

Governance: 76.5

Financial Health

Updated on: 07/12/2023

DCF: Strong Buy

ROE: Neutral

ROA: Neutral

Debt to equity ratio: Neutral

Price to earnings ratio: Strong Buy

Price to book ratio: Strong Buy

LGND Discounted Cash Flow

Updated on: 07/12/2023

$79.669
Discounted Cash Flow Value


$59.770
Current Price

LGND Revenues by Segment

Updated on: 07/12/2023

Contract Revenue
$192,230.00
License Fees
$28,490.00
License Fees, Milestones, and Other Product, Other
$61,070.00
Material Sales, Captisol
$1,044,950.00
Material Sales, Captisol, COVID
$880,660.00
Material Sales, Captisol, Core
$164,290.00
Milestone
$91,500.00
Royalty
$725,270.00
Royalty, Evomela
$101,970.00
Royalty, Kyprolis
$301,160.00
Royalty, Other
$76,330.00
Service
$11,170.00

Revenue from Contract with Customer, Excluding Assessed Tax

LGND Revenues by Region

Updated on: 07/12/2023

No available data

LGND Notes Due

Updated on: 07/12/2023

CIKExchangeTitle
0000886163 NASDAQ Preferred Share Purchase Rights
0000886163 PNK Preferred Share Purchase Rights

Ligand Pharmaceuticals (LGND) Social Sentiments

Monitoring bullish and bearish sentiments towards Ligand Pharmaceuticals on Twitter and Stocktwits could help to forecast an upward or downward trend in Ligand Pharmaceuticals stock price.

Promising Stock Forecast for Ligand Pharmaceuticals: Investing in a Leading Biopharmaceutical Company

Ligand Pharmaceuticals (LGND) is a leading biopharmaceutical company that specializes in inventing, developing, and delivering novel drugs for various diseases. Established in 1987, the San Diego-based company has revolutionized drug discovery through its proprietary technology platform that makes it easier to understand protein-ligand interactions. Ligand Pharmaceuticals is publicly traded on NASDAQ with LGND as its stock ticker. As of this... Read more

Stock Prediction: Ligand Pharmaceuticals' Biotech Success with Impressive Partnerships

The biotechnology sector has been one of the most exciting areas of the stock market in recent years. With incredible advancements and discoveries being made every day, investors are increasingly interested in companies that operate in this space. One such company is Ligand Pharmaceuticals, with stock ticker Biotechnology. Ligand Pharmaceuticals is a biotechnology company that focuses on developing and discovering... Read more